These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33341085)

  • 1. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Zhang Y; Chen S; Chen H; Li W
    Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
    Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
    Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.
    Ni XF; Wu J; Ji M; Shao YJ; Xu B; Jiang JT; Wu CP
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):402-409. PubMed ID: 30178541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
    Kasajima M; Igawa S; Manaka H; Yamada K; Akazawa Y; Manabe H; Yagami Y; Yamamoto H; Ito H; Kaizuka N; Nakahara Y; Sato T; Mitshufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
    Oncology; 2023; 101(1):69-76. PubMed ID: 36103811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
    Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
    Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
    Jiang AG; Lu HY
    J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
    Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
    Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
    J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents.
    Freitas C; Jacob M; Tavares N; Cruz-Martins N; Souto-Moura C; Araújo D; Novais-Bastos H; Santos V; Fernandes G; Magalhães A; Hespanhol V; Queiroga H
    Anticancer Drugs; 2021 Jun; 32(5):567-574. PubMed ID: 33661189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Horstman IM; Vinke PC; Suazo-Zepeda E; Hiltermann TJN; Heuvelmans MA; Corpeleijn E; de Bock GH
    Thorac Cancer; 2024 Aug; 15(23):1764-1771. PubMed ID: 39030876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies.
    Tanaka T; Yoshida T; Masuda K; Takeyasu Y; Shinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    Respir Investig; 2023 Jan; 61(1):74-81. PubMed ID: 36460585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study.
    Kasahara K; Enomoto M; Udo R; Tago T; Mazaki J; Ishizaki T; Yamada T; Nagakawa Y; Katsumata K; Tsuchida A
    BMC Cancer; 2022 Jan; 22(1):20. PubMed ID: 34980009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.